MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/220/0.1/19.12.25 | Market Closed - Börse Stuttgart 16:59:23 01/07/2024 BST | ||
| 0.71 EUR | +4.41% |
|
| Current month | +4.41% | ||
| 1 month | +42.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 01/07/24 | 0.71 | +4.41% |
| 28/06/24 | 0.68 | -1.45% |
| 27/06/24 | 0.69 | +1.47% |
| 26/06/24 | 0.68 | -11.69% |
| 25/06/24 | 0.77 | +24.19% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 04:59 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MG4DG4 |
| ISIN | DE000MG4DG44 |
| Date issued | 17/05/2024 |
| Strike | 220 $ |
| Maturity | 19/12/2025 (536 Days) |
| Parity | 10 : 1 |
| Emission price | 0.59 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.77 € |
|---|---|
| Lowest since issue | 0.45 € |
| Spread | 0.01 € |
| Spread % | 1.39% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,005
DKK
Average target price
950.4
DKK
Spread / Average Target
-5.39%
- Stock Market
- Warrants
- Warrant
